How is the FIB-4 score calculated?

The FIB-4 formula is: (Age × AST) ÷ (Platelet count × √ALT), where age is in years, AST and ALT are in U/L, and platelet count is in units of 10⁹/L. The calculation produces a single numerical score that categorizes individuals into low, indeterminate, or high risk for advanced fibrosis. Most laboratory systems and online calculators can compute this automatically from standard blood work.

What blood tests are needed to calculate a FIB-4 score?

Only three blood test values plus your age are needed: AST (aspartate aminotransferase), ALT (alanine aminotransferase), and platelet count. These are commonly included in standard metabolic panels and complete blood counts, meaning a FIB-4 score can often be calculated from labs you may already be getting. No specialized or expensive testing is required.

FIB-4 Score: Calculation, Results & What They Mean for Your Liver

Creator: Superpower
Published: 2026-04-03

Understand what your liver function testing results really mean

See your biomarkers in context with a comprehensive panel.

CLIA-certified labs
HIPAA compliant
Personalized health protocol

Book your test

Quick answer: The FIB-4 score is a simple calculation using age, AST, ALT, and platelet count to estimate the likelihood of significant liver fibrosis (scarring). It was originally developed for hepatitis C and is now used broadly as a non-invasive screening tool for liver fibrosis in the context of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). A score below 1.30 makes significant fibrosis unlikely; a score above 2.67 warrants further clinical evaluation.

What the FIB-4 score measures

Liver fibrosis is the accumulation of scar tissue within the liver, typically occurring in response to sustained inflammation or injury. In early stages, fibrosis may produce no symptoms and no abnormalities on standard liver function tests — making non-invasive screening tools particularly valuable. The FIB-4 score was developed as a way to use routinely available blood test data to estimate the probability of clinically significant fibrosis without requiring liver biopsy or advanced imaging.

The score does not confirm fibrosis — it stratifies risk. A low FIB-4 score indicates that advanced fibrosis is unlikely, while a high score indicates that further evaluation (such as liver elastography or biopsy) is warranted. The FIB-4 is not a standalone diagnostic tool; it is a triage and monitoring instrument used in clinical context.

How FIB-4 is calculated

The formula

The FIB-4 calculation uses four variables that are available from standard blood panels:

FIB-4 = (Age [years] × AST [U/L]) / (Platelet count [10⁹/L] × √ALT [U/L])

For example, a 50-year-old with AST of 45 U/L, ALT of 36 U/L, and a platelet count of 200 × 10⁹/L would have:

FIB-4 = (50 × 45) / (200 × √36) = 2,250 / (200 × 6) = 2,250 / 1,200 = 1.88

This result would fall in the intermediate zone, warranting clinical assessment and potentially additional testing.

What each variable contributes

Age: Older age is associated with a higher likelihood of significant fibrosis for any given degree of liver inflammation, reflecting the cumulative nature of fibrotic change over time.
AST (aspartate aminotransferase): An enzyme released when hepatocytes (liver cells) are damaged. Elevated AST reflects hepatocellular injury. In later-stage fibrosis, the AST/ALT ratio tends to rise above 1 as regenerative capacity declines.
ALT (alanine aminotransferase): A more liver-specific enzyme than AST; elevated ALT is a sensitive indicator of active hepatocellular inflammation.
Platelet count: As fibrosis advances to cirrhosis, portal hypertension and splenic sequestration reduce platelet count. Falling platelets are therefore an indirect marker of advancing liver disease. A declining platelet count over serial measurements is a particularly informative trend.

Interpreting FIB-4 results

<1.30 — Low risk of significant fibrosis (F0–F1); routine monitoring with attention to metabolic risk factors
1.30–2.67 — Intermediate, indeterminate zone; clinical assessment recommended, and liver elastography or additional non-invasive tests may be considered
>2.67 — elevated risk of advanced fibrosis or cirrhosis (F3–F4); hepatology referral recommended with liver elastography or biopsy for confirmation

Reference cut-offs are based on validation studies in hepatitis C and MASLD populations. In individuals over 65, the FIB-4 score tends to be higher due to the age variable, and some guidelines recommend higher cut-off thresholds for older patients to avoid overcalling risk. Reference ranges and appropriate thresholds vary by clinical context; all results should be interpreted by a qualified provider.

Where FIB-4 is most commonly used

Metabolic dysfunction-associated steatotic liver disease (MASLD)

MASLD (previously called non-alcoholic fatty liver disease or NAFLD) is the most common liver condition in many high-income countries, affecting an estimated 25–38% of adults globally. It ranges from simple hepatic steatosis (fat accumulation without inflammation) to metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with inflammation and fibrosis, which can progress to cirrhosis and hepatocellular carcinoma. Because most people with MASLD are asymptomatic in early stages, the FIB-4 score provides a non-invasive way to identify individuals who may already have significant fibrosis and require further evaluation.

Multiple clinical guidelines — including those from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) — endorse the FIB-4 score as a first-line non-invasive test for liver fibrosis assessment in the primary care and general medicine setting.

Monitoring over time

Serial FIB-4 measurements over months to years can track the trajectory of liver health. A stable or declining score alongside metabolic improvements — such as weight reduction, improved HbA1c, and lower triglycerides — suggests that fibrosis risk is being managed. A rising score despite apparently normal liver enzyme levels is a signal for closer evaluation.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

Limitations of the FIB-4 score

The FIB-4 has meaningful limitations. Conditions that independently alter any of its component values can distort the result. Elevated AST from muscle injury, hemolysis, or cardiac sources rather than liver damage will artifactually raise the score. Thrombocytopenia from non-hepatic causes (such as immune thrombocytopenia or chemotherapy) will similarly inflate it. The score performs best in populations with a meaningful prevalence of liver disease; in very low-risk populations, positive predictive value decreases. It is also poorly validated in pediatric populations and in individuals with certain viral infections. Clinicians use FIB-4 as one input, not the sole determinant of liver health assessment.

Biomarkers needed to calculate FIB-4

AST — liver enzyme; reflects hepatocellular injury
ALT — liver enzyme; liver-specific marker of inflammation
Platelet count — Declines with advancing fibrosis and portal hypertension. Included in the Baseline Blood Panel CBC
Age — Input variable incorporated into the formula directly

All four inputs needed to calculate a FIB-4 score — AST, ALT, and platelet count — are included in Superpower's Baseline Blood Panel. Metabolic context markers that inform liver health in a broader sense — including fasting glucose, HbA1c, triglycerides, and fasting insulin — are also part of the standard panel.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health routine. Superpower offers blood panels that include the biomarkers needed to calculate FIB-4. Links to individual tests are provided for informational context.

Frequently Asked Questions

The FIB-4 (Fibrosis-4) score is a validated, non-invasive index used to estimate the likelihood and degree of liver fibrosis, which is the buildup of scar tissue in the liver. It was developed as a simpler alternative to liver biopsy for initial screening and risk stratification. The score is calculated from four readily available variables: age, AST (aspartate aminotransferase), ALT (alanine aminotransferase), and platelet count.

A FIB-4 score below 1.30 is generally considered low risk for advanced fibrosis, with a high negative predictive value for ruling out significant scarring. Scores between 1.30 and 2.67 fall into an indeterminate zone that may require additional testing. A score above 2.67 is associated with a higher likelihood of advanced fibrosis and typically warrants further evaluation such as imaging or elastography.

A high FIB-4 score (above 2.67) suggests an increased likelihood of advanced liver fibrosis or cirrhosis. However, the score is a screening tool, not a definitive diagnosis, and elevated results should be confirmed with additional assessments such as transient elastography (FibroScan) or imaging. Factors like acute illness, muscle damage, or certain medications can temporarily elevate AST or lower platelets, potentially inflating the score.

Current guidelines suggest FIB-4 screening for individuals with risk factors for liver fibrosis, including those with non-alcoholic fatty liver disease, type 2 diabetes, obesity, chronic hepatitis B or C, or significant alcohol consumption. It is also increasingly recommended as a screening tool for adults with metabolic risk factors such as obesity, type 2 diabetes, or metabolic syndrome. Because it uses standard blood work, it is a practical first step before more invasive or costly liver assessments.

The FIB-4 score has a strong negative predictive value, meaning a low score is generally considered reliable for helping rule out advanced fibrosis in validation studies. Its positive predictive value is more moderate, so a high score indicates increased risk but does not confirm fibrosis on its own. For this reason, elevated or indeterminate scores are typically followed up with additional tests such as elastography to improve diagnostic accuracy.

Liver biopsy is considered the gold standard for staging fibrosis but is invasive, carries a small risk of complications, and can be subject to sampling variability. The FIB-4 score provides a non-invasive, cost-free initial screening step that can help identify individuals at lower risk, which may reduce the need for biopsies. For those with elevated scores, it serves as a triage tool to determine who should proceed to further evaluation.